Pharma Report 2012: Get Back in Shape

Share this article:
Pharma Report 2012: Get Back in Shape
Pharma Report 2012: Get Back in Shape

10    Johnson & Johnson    $12.1B     down 6.2%
Global revenue: $65.0B (2nd); up 5.5%

R&D spend: $7.5B (5th), up 10.3%; 11.5% of rev.

Top brands: Remicade ($3.5B), Procrit ($1.2B), Concerta ($856M), Levaquin ($778), Prezista ($630M)

Planned launches: Canagliflozin (diab.), TMC-435 (HCV), bapineuzumab (Alz.)

Promotional spend: $438M (13th); 3.6% of rev.

Patent expirations: Remicade (2014), Prezista (2016), Zytiga (2016)

J&J's past year can be summed up in one word: recalls. The healthcare products giant had a lot of them, fueling discussions of a company that has lost its luster. This came in addition to lawsuits alleging fraudulent marketing of its antipsychotic Risperdal. The impact of these missteps shows: the government shutdown of a McNeil plant hurt inventory levels, and OTC sales fell 3% in the US last year. But a recent poll showed consumers are still attached to J&J. CEO William Weldon, who was in place during much of the product recalls, was replaced by Alex Gorsky.

Back to first page

Page 10 of 21
Share this article:

Email Newsletters

More in Features

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...